Loxapine

IntelGenx Reports First Quarter 2023 Financial Results

Retrieved on: 
Thursday, May 11, 2023
Patent, Webcast, Pharma, Total, Migraine, International, Senior, General counsel, Prevalence, Symantec Endpoint Protection, Corporate development, United States Patent and Trademark Office, IGX, Clinical trial, Ageing, MBA, Doctor of Philosophy, Trial of the century, Administration, Retirement, Investment, Karolinska Institute, CPA, CFO, TSX, Depreciation, ANDA, Research, Regulation of tobacco by the U.S. Food and Drug Administration, Loxapine, Conference, Alzheimer's disease, Food, Cryptocurrency, Bookkeeping, Video game, Pharmaceutical industry, MD

SAINT LAURENT, Quebec, May 11, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the first quarter ended March 31, 2023.

Key Points: 
  • SAINT LAURENT, Quebec, May 11, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the first quarter ended March 31, 2023.
  • 2023 First Quarter Financial Summary:
    Revenue was $162,000, compared to $237,000 in the 2022 first quarter.
  • Operating costs and expenses were $2.8 million for the first quarter of 2023, versus $2.5 million for the corresponding three-month period of 2022.
  • IntelGenx will host a conference call to discuss these first quarter 2023 financial results today at 4:30 p.m.

IntelGenx Reports Fourth Quarter and Full-Year 2022 Financial Results

Retrieved on: 
Wednesday, March 29, 2023
Buccal, Patent, Webcast, International, University, Quarter, Bank statement, United States Patent and Trademark Office, NDA, University of Prince Edward Island, Form 10-K, Doctor of Philosophy, Trial of the century, EBITDA, Investment, Karolinska Institute, PDUFA, TSX, Growth, Cat, R, ANDA, Annual report, Regulation of tobacco by the U.S. Food and Drug Administration, Loxapine, Conference, Food, Cryptocurrency, Pharmaceutical industry, Video game, Bookkeeping, Security (finance), MD

SAINT LAURENT, Quebec, March 29, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the three- and twelve-month periods ended December 31, 2022.

Key Points: 
  • SAINT LAURENT, Quebec, March 29, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the three- and twelve-month periods ended December 31, 2022.
  • Net comprehensive loss was $2.3 million, compared to $2.9 million in the 2021 fourth quarter.
  • Operating costs and expenses were $2.7 million for the fourth quarter of 2022, versus $3.0 million for the corresponding three-month period of 2021.
  • IntelGenx will host a conference call to discuss these 2022 fourth quarter and full year financial results today at 4:30 p.m.

IntelGenx Receives USPTO Notice of Allowance for Loxapine Orange Book Eligible Patent

Retrieved on: 
Tuesday, February 21, 2023
Intermittent explosive disorder, Caregiver, Patent, TSX, Loxapine, Intellectual property, Patient, Agitation, Schizophrenia, Anxiety, IGX, DSM-IV codes, Pharmaceutical industry

SAINT LAURENT, Quebec, Feb. 21, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx”), a leader in pharmaceutical films, today announced that the United States Patent and Trademark Office (“USPTO”) has granted a Notice of Allowance for U.S. Patent Application 16/053,383, entitled "Loxapine Film Oral Dosage Form.”

Key Points: 
  • SAINT LAURENT, Quebec, Feb. 21, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx”), a leader in pharmaceutical films, today announced that the United States Patent and Trademark Office (“USPTO”) has granted a Notice of Allowance for U.S. Patent Application 16/053,383, entitled "Loxapine Film Oral Dosage Form.”
    This film formulation patent covers Loxapine oral film formulations designed for use in patients with anxiety and agitation associated with schizophrenia and bipolar 1 disorder, and is intended to protect IntelGenx' Loxapine VersaFilm® product.
  • The new, soon to be patented, Loxapine oral film technology is designed to provide quick onset and a simple administration process for schizophrenia and bipolar 1 disorder patients.
  • "The granting of this notice of allowance for a formulation specific orange book eligible patent for our Loxapine oral film validates the innovative work carried out on this project by our talented R&D team," said Horst G. Zerbe, CEO of IntelGenx.
  • "While expanding our overall intellectual property portfolio, this new patent also solidifies the potential long-term market exclusivity of our unique Loxapine VersaFilm® product candidate."

NRx Pharmaceuticals Announces the Appointment of Carrie M. Carretta, PhD, APN-BC, AHN-BC, PMHNP, Senior Vice President of Clinical Development and Medical Affairs

Retrieved on: 
Monday, December 5, 2022
Therapy, Post-traumatic stress disorder, Medical Affairs Bureau, Sacubitril/valsartan, Schizophrenia, Medicine, Neurological disorder, PMHNP, Food, Executive director, Novartis, Doctor of Philosophy, Wellness, Patient, State university system, NMDA, Dark Enlightenment, FDA Special Protocol Assessment, Interferon beta-1b, Knowledge, Nursing, Stanford University, Bureau of Oceans and International Environmental and Scientific Affairs, FDA, Vanderbilt University, Loxapine, Breakthrough, Forensic psychiatry, Teva Pharmaceuticals, Food and Drug Administration, Ketamine, Senior, Spectrum, Bayer, Boehringer Ingelheim, Juul, Mental health, Depression, Suicide, CNS, Healthcare, Pharmaceutical industry, Management, Secukinumab, Rutgers University, PTSD

She will lead the Company's clinical development program and provide medical oversight across all indications.

Key Points: 
  • She will lead the Company's clinical development program and provide medical oversight across all indications.
  • NRx Pharmaceuticals Announces the Appointment of Carrie M. Carretta, PhD, APN-BC, AHN-BC, PMHNP, Senior Vice President of Clinical Development and Medical Affairs
    "The NRx team is excited to have attracted a clinician with deep experience as an investigator.
  • Dr. Carretta's wealth of knowledge will help drive our mission to develop a first-in-class lifesaving drug for suicidal depression and PTSD.
  • Prior to this role, Dr. Carretta served as the Vice President, Medical and Scientific Affairs at Pendulum Therapeutics.